Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma

BACKGROUND: Patients with sarcomatoid renal cell carcinomas (sRCC) have poor outcomes and limited treatment options. Pre-clinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase II trial to evaluate the effic...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Genitourin Cancer
Prif Awduron: Maiti, Abhishek, Nemati-Shafaee, Maryam, Msaouel, Pavlos, Pagliaro, Lance C., Jonasch, Eric, Tannir, Nizar M., Shah, Amishi Y.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809227/
https://ncbi.nlm.nih.gov/pubmed/28870517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.028
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg